评估综合性瘤学模式的症状管理:一个MASCC/SIO全球调查
Alexandre Chan1, Reem Nasr2, Daniela Arcos2
1Department of Clinical Pharmacy Practice, University of California Irvine, 802 W Peltason Drive, Irvine, CA, 92697-4625, USA. a.chan@uci.edu.
BMC complementary medicine and therapies
|November 4, 2025
概括
大多数癌症护理利益相关者使用或推综合性瘤学 (IOM) 模式来治疗症状,但认为它们未得到充分利用. 教育的区域差异和财务障碍影响国际移民组织的全球使用.
科学领域:
- 综合性瘤学 综合性瘤学
- 支持性癌症护理 支持性癌症护理
- 全球健康 全球健康
背景情况:
- 越来越多的证据支持综合性瘤学模式 (IOM) 治疗癌症和与治疗相关的症状.
- 对IOM利用和实施的研究对于优化支持性癌症护理至关重要.
- 本研究探讨了全球利益相关者对癌症护理整合性瘤学 (IO) 的观点.
研究的目的:
- 检查全球利益相关者对综合性瘤学 (IO) 在支持性癌症护理中的利用的观点.
- 识别不同地区IOM使用,教育和财务考虑的模式.
主要方法:
- 一项调查分发给了多国癌症支持护理协会 (MASCC) 和综合性瘤学会 (SIO) 的成员.
- 描述性统计分析了人口统计数据,IOM使用模式,IOM教育和财务方面.
- 来自八个地理区域的344名参与者完成了调查.
主要成果:
- 70%的参与者使用或推IOM; 79%的参与者认为IOM在癌症治疗中未得到充分利用.
- 最常使用的IOM包括针,运动,营养和呼吸/治疗情绪,疼痛,胃肠道和疲劳症状.
- 在国际移民组织教育的可用性和共同的国际移民组织建议方面存在区域差异,并指出了金融障碍.
结论:
- 大多数受访者使用IOM,但在全球范围内存在明显的感知不足利用情况.
- 综合性瘤学教育的区域差异和财务限制对IOM实施构成障碍.
- 需要进一步的研究来解决这些障碍,并支持IO在癌症治疗中的整合.
相关概念视频
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
725
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
725
